BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15988036)

  • 21. Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
    Tanabe T
    Hiroshima J Med Sci; 2000 Mar; 49(1):67-72. PubMed ID: 10824459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion.
    Okada SS; Grobmyer SR; Barnathan ES
    Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1269-76. PubMed ID: 8857924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1.
    Sipley JD; Alexander DS; Testa JE; Quigley JP
    Proc Natl Acad Sci U S A; 1997 Apr; 94(7):2933-8. PubMed ID: 9096324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
    Biliran H; Sheng S
    Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
    Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
    J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
    Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
    Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.
    Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC
    Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
    Allan EH; Martin TJ
    J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human gingival fibroblast migration promoted by platelet-derived growth factor on titanium is correlated with release of urokinase type plasminogen activator.
    Abiko Y; Arai J; Matsuzawa K; Inoue T; Shimono M; Kaku T
    Bull Tokyo Dent Coll; 1996 Aug; 37(3):113-8. PubMed ID: 9151567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin.
    Festuccia C; Guerra F; D'Ascenzo S; Giunciuglio D; Albini A; Bologna M
    Int J Cancer; 1998 Jan; 75(3):418-31. PubMed ID: 9455804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1.
    Mikolajczyk SD; Millar LS; Kumar A; Saedi MS
    Int J Cancer; 1999 May; 81(3):438-42. PubMed ID: 10209959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator.
    Reinartz J; Schaefer B; Bechtel MJ; Kramer MD
    Exp Cell Res; 1996 Feb; 223(1):91-101. PubMed ID: 8635500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
    FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence of a non-conventional role for the urokinase tripartite complex (uPAR/uPA/PAI-1) in myogenic cell fusion.
    Bonavaud S; Charrière-Bertrand C; Rey C; Leibovitch MP; Pedersen N; Frisdal E; Planus E; Blasi F; Gherardi R; Barlovatz-Meimon G
    J Cell Sci; 1997 May; 110 ( Pt 9)():1083-9. PubMed ID: 9175704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
    Lokker NA; Sullivan CM; Hollenbach SJ; Israel MA; Giese NA
    Cancer Res; 2002 Jul; 62(13):3729-35. PubMed ID: 12097282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells.
    Kong D; Banerjee S; Huang W; Li Y; Wang Z; Kim HR; Sarkar FH
    Cancer Res; 2008 Mar; 68(6):1927-34. PubMed ID: 18339874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy.
    Lei H; Velez G; Hovland P; Hirose T; Kazlauskas A
    Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):42-8. PubMed ID: 18172073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
    Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
    Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.
    Al-Ejeh F; Croucher D; Ranson M
    Exp Cell Res; 2004 Jul; 297(1):259-71. PubMed ID: 15194441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer.
    Demetriou MC; Pennington ME; Nagle RB; Cress AE
    Exp Cell Res; 2004 Apr; 294(2):550-8. PubMed ID: 15023541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.